US Securities Regulator Probes Illumina Over Grail Deal
The SEC has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail, the gene sequencing company said in a regulatory filing.
Reuters Health Information
source https://www.medscape.com/s/viewarticle/995375?src=rss
Reuters Health Information
source https://www.medscape.com/s/viewarticle/995375?src=rss
Comments
Post a Comment